JTC’s Post

The antibody–drug conjugate (ADC) landscape is rapidly evolving and has become a significant therapeutic modality in oncology. The publication offers a nice overview of the ADC landscape. https://lnkd.in/eSGNKSEB

📣 ICYMI📣 July's Resource Roundup includes: 📖 How to set up your CDMS/EDC to overcome staffing challenges and grow with you 📊 What other small biopharma orgs and CROs think about the latest eClinical trends 🏥 Meeting the regulatory push for Real-Time Oncology Review (RTOR) while executing mid-study changes Learn more here: https://bit.ly/3W2xbVT #EDC #CDMS #Oncology #Biotech #CRO #DataQuality #ClinicalDataManagement #ClinicalTrials

If you are a pioneering #biotech, #medicaldevice, or #diagnostics company, great insights in this month's Medrio Resource Roundup, including: - Thoughts on selecting technology to serve small teams and to extend your cash runway - Insight into the types of #clinicalresearch technologies that other #lifesciences companies are using as they evolve into #earlyphase trials

Pharma companies can help patients access biomarker testing by providing resources on patient identification, available vendors, proof of eligibility, and ordering instructions. MMIT and The Dedham Group share tips for oncology manufacturers in Drug Channels: https://ow.ly/Vj2U30sFK4I. #Pharma #PharmaManufacturers #MarketAccess #Oncology

Setting realistic expectations for how payer coverage is likely to build over time is critical for pharma companies. https://ow.ly/UAB250SjbFW In this case study, learn how one small oncology biopharma used MMIT’s coverage uptake analysis for new drugs to prepare for the launch of its therapy. #FDA #Oncology #Biopharma #BiopharmaInsights #MarketAccess

To run a successful oncology development program under the FDA's Project Optimus, it's crucial to focus on identifying the optimal dose range for your asset. In our latest blog, James Matcham and Mike Fossler provide valuable insights into Project Optimus and discuss key factors that can enhance your chances of success. Read the full article: https://bit.ly/3W8e2Dc #FDAProjectOptimus #FDA #Oncology #oncologydevelopment #clinicaltrials #optimaldose #drugdevelopment #pharma #biotech

#radonc: what reading material would you rec for newly #MatchDay2024 students interested in learning about the history of radiation oncology? We covered some in our history chapter in the Radiopharmaceutical Therapy book, but not a proper dive (https://lnkd.in/guFcjB7t) TIA!

Dr. Roy Baynes of Eikon Therapeutics joined us to discuss his process of developing pembrolizumab, also known as Keytruda. Applying his experience as CMO and Head of Development at Merck, he explains what it takes to successfully develop an oncology therapeutic. Read the article here: https://lnkd.in/eCwvmyvV! #ClinicalTrials #DrugDevelopment #Keytruda

Here is a great background blog for next week's workshop! #AACRSciencePolicy

🔬 Revolutionize oncology care with TuMinimize! Our advanced therapeutic drug monitoring tool ensures that each cancer patient receives precisely the right dose of biologics, tailored to their unique treatment needs. By optimizing dosage, TuMinimize enhances outcomes, reduces adverse effects, and supports healthcare professionals in providing truly personalized care. Learn more: https://lnkd.in/eZB_YbXz. #Oncology #PrecisionMedicine